NT5E and neoplasm: Using a selective A2A adenosine receptor antagonist and CD73 inhibitor in combination improved the outcomes of DC-based cancer vaccination, reducing tumor growth, prolonging mouse survival, and enhancing specific antitumor immune responses [52].